Skip to main content

Myocardial Infarction

55
Pipeline Programs
30
Companies
50
Clinical Trials
2 recruiting
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
2
8
2
16
25
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1158%
Small Molecule
632%
RNA Therapeutic
15%
Peptide
15%
+ 131 programs with unclassified modality

On Market (4)

Approved therapies currently available

Boehringer Ingelheim
JARDIANCEApproved
empagliflozin
Boehringer Ingelheim
Sodium-Glucose Cotransporter 2 Inhibitor [EPC]oral2014
8.8B Part D
AstraZeneca
BRILINTAApproved
ticagrelor
AstraZeneca
P2Y12 Platelet Inhibitor [EPC]oral2011
692M Part D
REOPROApproved
abciximab
Unknown Company
injection1994
Roche
TNKASEApproved
tenecteplase
Roche
2000

Competitive Landscape

65 companies ranked by most advanced pipeline stage

Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
14 programs
1
AlteplaseN/A1 trial
METALYSE®N/A1 trial
MetalyseN/A1 trial
Metalyse weight-adjustedN/A1 trial
coronary balloon-angioplasty with stentingN/A
+9 more programs
Active Trials
NCT02235389Terminated59
NCT02191670Completed60
NCT02206646Completed987
+9 more trials
Prevail Therapeutics
12 programs
1
6
3
AbciximabPhase 4Monoclonal Antibody
AbciximabPhase 4Monoclonal Antibody
abciximabPhase 4Monoclonal Antibody
AbciximabPhase 3Monoclonal Antibody
Coronary AngioplastyPhase 3
+7 more programs
Medtronic
11 programs
1
2
2
6 months DAPTPhase 41 trial
Everolimus eluting stentPhase 41 trial
Eptifibatide facilitated PCIPhase 31 trial
Implantable Cardioverter Defibrillator + Usual CarePhase 3
PCIPhase 2
+6 more programs
Active Trials
NCT02124018Completed575Est. Jul 2018
NCT05307965Completed81Est. May 2025
NCT02939976Terminated427Est. Jul 2023
+3 more trials
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
10 programs
1
2
3
TicagrelorPhase 41 trial
TicagrelorPhase 41 trial
TicagrelorPhase 41 trial
MD-endorsed Cardiac Rehabilitation referralPhase 31 trial
Ticagrelor 90 mgPhase 31 trial
+5 more programs
Active Trials
NCT01874262Completed174Est. Dec 2014
NCT03099395Unknown100,000Est. Oct 2017
NCT00679575Completed13,171Est. Nov 2010
+7 more trials
Innovation Pharmaceuticals
4 programs
1
1
Postfibrinolysis percutaneous coronary interventionPhase 41 trial
Implantable Cardioverter Defibrillator + Usual CarePhase 3
Arrhythmias in Post-Myocardial Infarction PatientsN/A
Safety of Nitroglycerin for Field Treatment of STEMIN/A
Active Trials
NCT00306228Completed436Est. Jan 2009
Roche
3 programs
1
Routine Early Percutaneous Coronary Intervention after ThrombolysisN/A
Spectral T Wave AlternansN/A
TNKASE(tenecteplase)PHASE_2_3
UNION therapeutics
3 programs
1
1
1
LevothyroxinePhase 41 trial
Bone marrow mesenchymal stem cells transferPhase 2/31 trial
AtorvastatinPhase 2Small Molecule1 trial
Active Trials
NCT03047772Unknown124Est. Dec 2018
NCT04421274Completed43Est. Jul 2011
NCT02512978Unknown160Est. Jun 2019
Boston Scientific
3 programs
1
1
1
rheolytic thrombectomy with direct stentingPhase 41 trial
BivalirudinPhase 31 trial
Left Atrial Appendage Closure DevicePhase 21 trial
Active Trials
NCT02492230Unknown50Est. Dec 2017
NCT00433966Completed3,602Est. Nov 2010
NCT00275990Completed501Est. Aug 2010
Pfizer
PfizerNEW YORK, NY
2 programs
2
EplerenonePhase 42 trials
Percutaneous coronary interventionPhase 4
Active Trials
NCT01971593Terminated26Est. Jun 2016
NCT01176968Completed1,012Est. Oct 2012
Sharp Therapeutics
2 programs
2
PrasugrelPhase 4
VorapaxarPhase 4
MSD
2 programs
2
PrasugrelPhase 41 trial
VorapaxarPhase 41 trial
Active Trials
NCT02545933Completed130Est. Jan 2020
NCT02548650Completed66Est. Feb 2019
ISU Abxis
1 program
1
ClotinabPhase 41 trial
Active Trials
NCT00841438Completed786Est. Dec 2009
Orion
1 program
1
HydroxychloroquinePhase 41 trial
Active Trials
NCT02648464Completed125Est. Dec 2019
Orion Pharma
1 program
1
HydroxychloroquinePhase 4
InspireMD
1 program
1
MGuardPhase 41 trial
Active Trials
NCT01368471Completed433Est. Jun 2012
Sandoz
2 programs
1
AliskirenPhase 3
Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI PatientsN/ARNA Therapeutic
Ferrer
2 programs
2
Cardiovascular PolypillPhase 31 trial
FDCPhase 31 trial
Active Trials
NCT02596126Completed2,499Est. Mar 2022
NCT01321255Completed2,118Est. Jun 2014
JW Pharmaceutical
1 program
1
NicorandilPhase 31 trial
Active Trials
NCT02449070Unknown86Est. Oct 2018
Bayer
2 programs
2
FulacimstatPhase 2Small Molecule1 trial
MagnevistPhase 21 trial
Active Trials
NCT02976467Completed107Est. Sep 2018
NCT00310544Completed73Est. Sep 2006
Quantum Genomics
1 program
1
RamiprilPhase 2Small Molecule
Nyrada
1 program
1
XolatrypPhase 21 trial
Active Trials
NCT07362446Recruiting300Est. Sep 2027
ViiV Healthcare
2 programs
1
Lovaza®Phase 1/2
OPTAMI (Optimized Therapy of Acute Myocardial Infarction) - RegistryN/A
Serpin Pharma
1 program
1
SP16Phase 1/21 trial
Active Trials
NCT04225533Completed10Est. Dec 2021
Ventrix
1 program
1
VentriGelPhase 11 trial
Active Trials
NCT02305602Completed15Est. Jun 2019
RegeneRx Biopharmaceuticals
1 program
1
thymosin beta 4Phase 11 trial
Active Trials
NCT00743769Withdrawn0Est. Jan 2017
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
5 programs
coronary balloon-angioplasty with stentingN/A
tenecteplasePHASE_2_3
AbciximabPHASE_3Monoclonal Antibody1 trial
Coronary AngioplastyPHASE_3
fibrinolytic therapy or combination reduced fibrinolytic therapyPHASE_31 trial
Active Trials
NCT00638638Unknown292Est. Jan 2010
NCT00245648CompletedEst. Oct 2007
Rhythm Pharmaceuticals
4 programs
Medtronic Reveal LINQ implantable cardiac monitorN/A1 trial
T Wave Alternans TestN/A1 trial
T Wave Alternans TestN/A1 trial
PCIPHASE_21 trial
Active Trials
NCT02594488Completed400Est. Feb 2021
NCT00305240Completed656Est. Feb 2007
NCT00305214Completed405Est. Feb 2007
+1 more trials
GE HealthCare
3 programs
Arrhythmias in Post-Myocardial Infarction PatientsN/A1 trial
Spectral T Wave AlternansN/A
Implantable Cardioverter Defibrillator + Usual CarePHASE_31 trial
Active Trials
NCT03231826Completed445Est. Feb 2019
NCT00673842Completed700Est. Oct 2024
Biotronik
BiotronikGermany - Berlin
3 programs
BioMonitorN/A1 trial
Implantable Cardio DefibrillatorN/A1 trial
Coronary AngioplastyPHASE_31 trial
Active Trials
NCT02341534Completed802Est. Nov 2021
NCT01422174Withdrawn0Est. Jan 2015
NCT00220571Completed600Est. Mar 2007
Philips
PhilipsNetherlands - Amsterdam
3 programs
CTN/A1 trial
TelemetryN/A1 trial
CoolingPHASE_2_31 trial
Active Trials
NCT00285064Completed20Est. May 2008
NCT02441582Completed19Est. Oct 2017
NCT01379261Completed120Est. Nov 2013

+35 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
RegeneronAlirocumab
Boehringer IngelheimTenecteplase
AstraZenecaTicagrelor
MSDVorapaxar
OrionHydroxychloroquine
MSDPrasugrel
UNION therapeuticsLevothyroxine
AstraZenecaTicagrelor
T-TherapeuticsDanhong Injection
PfizerEplerenone
Medtronic6 months DAPT
AstraZenecaTicagrelor
InspireMDMGuard
Vera TherapeuticsCYP2C19 genotyping
PfizerEplerenone

Showing 15 of 49 trials with date data

Clinical Trials (50)

Total enrollment: 64,237 patients across 50 trials

NCT03750760RegeneronAlirocumab

Early Alirocumab to Reduce LDL-C in Myocardial Infarction

Start: Jan 2020Est. completion: Dec 20210
Phase 4Withdrawn
NCT02777580Boehringer IngelheimTenecteplase

STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction

Start: Aug 2017Est. completion: Sep 2023609 patients
Phase 4Completed
NCT02663713AstraZenecaTicagrelor

A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction

Start: Jan 2017Est. completion: Jun 201720 patients
Phase 4Completed
NCT02548650MSDVorapaxar

Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus

Start: Mar 2016Est. completion: Feb 201966 patients
Phase 4Completed
NCT02648464OrionHydroxychloroquine

Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial

Start: Feb 2016Est. completion: Dec 2019125 patients
Phase 4Completed
NCT02545933MSDPrasugrel

Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

Start: Feb 2016Est. completion: Jan 2020130 patients
Phase 4Completed
NCT02512978UNION therapeuticsLevothyroxine

Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction(ThyroHeart-AMI)

Start: Aug 2015Est. completion: Jun 2019160 patients
Phase 4Unknown
NCT02233790AstraZenecaTicagrelor

Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI

Start: Dec 2014Est. completion: Dec 2016600 patients
Phase 4Unknown
NCT02158559T-TherapeuticsDanhong Injection

the Effect of Danhong Injection on Microcirculation in the Treatment of Patients With STEMI After the PTCA Surgery.

Start: Mar 2014
Phase 4Unknown
NCT01971593PfizerEplerenone

The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease

Start: Aug 2013Est. completion: Jun 201626 patients
Phase 4Terminated
NCT01459627Medtronic6 months DAPT

Randomized, Open Label Trial of 6 Months Versus 12 Months DAPT After Drug-Eluting Stent in STEMI

Start: Dec 2011Est. completion: Aug 20171,100 patients
Phase 4Completed
NCT01347580AstraZenecaTicagrelor

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Start: Sep 2011Est. completion: Nov 20131,875 patients
Phase 4Completed
NCT01368471InspireMDMGuard

Safety and Efficacy Study of MGuard Stent After a Heart Attack

Start: Jun 2011Est. completion: Jun 2012433 patients
Phase 4Completed
NCT01761786Vera TherapeuticsCYP2C19 genotyping

Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics)

Start: Jun 2011Est. completion: Apr 2019
Phase 4Completed
NCT01176968PfizerEplerenone

Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction

Start: Sep 2010Est. completion: Oct 20121,012 patients
Phase 4Completed
NCT01347554MedtronicEverolimus eluting stent

Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction

Start: Jan 2009Est. completion: Mar 2013461 patients
Phase 4Completed
NCT00841438ISU AbxisClotinab

Efficacy of Early Administration of Clotinab in Acute Myocardial Infarction

Start: Jul 2007Est. completion: Dec 2009786 patients
Phase 4Completed
NCT00440778CordisAbciximab

A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI

Start: Feb 2007Est. completion: Oct 2008105 patients
Phase 4Completed
NCT00440895CordisAbciximab

A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI and Rescue-PCI

Start: Feb 2007Est. completion: May 201374 patients
Phase 4Completed
NCT00422565CordisEndeavor, Medtronic

Zotarolimus-Versus Sirolimus-Versus PacliTaxel-Eluting Stent for Acute Myocardial Infarction Patients

Start: Oct 2006Est. completion: Sep 2008328 patients
Phase 4Terminated
NCT00275990Boston Scientificrheolytic thrombectomy with direct stenting

AngioJET Thrombectomy and STENTing for Treatment of Acute Myocardial Infarction

Start: Dec 2005Est. completion: Aug 2010501 patients
Phase 4Completed
NCT00138034SanofiPercutaneous coronary intervention

APRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3

Start: Jan 2005Est. completion: Feb 201049 patients
Phase 4Completed
NCT00162331Lantheus Medical ImagingTechnetium Tc99m Sestamibi

CARDIOLITE-413: A Study for Patients Who Had a PCI for an Acute MI

Start: Jan 2005Est. completion: Jul 200774 patients
Phase 4Completed
NCT00306228Innovation PharmaceuticalsPostfibrinolysis percutaneous coronary intervention

Role of Tirofiban and the Paclitaxel Eluting Stent in Postfibrinolysis Angioplasty

Start: Oct 2004Est. completion: Jan 2009436 patients
Phase 4Completed
NCT00168792GenentechTenecteplase

A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)

Start: Nov 20031,671 patients
Phase 4Terminated
NCT01245725MedicureTirofiban

Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention

0
Phase 3Withdrawn
NCT07301034Novo NordiskZiltivekimab

A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack

Start: Dec 2025Est. completion: Feb 2029332 patients
Phase 3Recruiting
NCT04509674Boehringer IngelheimEmpagliflozin

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

Start: Dec 2020Est. completion: Nov 20236,522 patients
Phase 3Completed
NCT02596126FerrerCardiovascular Polypill

Secondary Prevention of Cardiovascular Disease in the Elderly Trial

Start: Jul 2016Est. completion: Mar 20222,499 patients
Phase 3Completed
NCT02449070JW PharmaceuticalNicorandil

Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction

Start: May 2015Est. completion: Oct 201886 patients
Phase 3Unknown
NCT01321255FerrerFDC

Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention.

Start: Jan 2012Est. completion: Jun 20142,118 patients
Phase 3Completed
NCT01327534Daiichi SankyoPrasugrel

Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute MI

Start: May 2011Est. completion: Jul 201363 patients
Phase 3Completed
NCT00673842GE HealthCareImplantable Cardioverter Defibrillator + Usual Care

Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

Start: Apr 2011Est. completion: Oct 2024700 patients
Phase 3Completed
NCT01225562AstraZenecaTicagrelor 90 mg

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Start: Oct 2010Est. completion: Dec 201421,379 patients
Phase 3Completed
NCT00623623Boehringer Ingelheimprimary PCI

STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction

Start: Mar 2008Est. completion: Sep 20121,899 patients
Phase 3Completed
NCT00251823MedtronicEptifibatide facilitated PCI

Safety and Efficacy Study of Eptifibatide in Primary Percutaneous Coronary Intervention (PCI)

Start: Jul 2005Est. completion: Sep 2008400 patients
Phase 3Completed
NCT00433966Boston ScientificBivalirudin

Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction

Start: Mar 2005Est. completion: Nov 20103,602 patients
Phase 3Completed
NCT00638638Eli Lilly and CompanyAbciximab

Myocardial Infarction With ST-Elevation

Start: Jan 2005Est. completion: Jan 2010292 patients
Phase 3Unknown
NCT00220571BiotronikCoronary Angioplasty

CARESS in Acute Myocardial Infarction

Start: May 2003Est. completion: Mar 2007600 patients
Phase 3Completed
NCT00336830AstraZenecaMD-endorsed Cardiac Rehabilitation referral

Improving Cardiac Rehabilitation Participation in Women and Men

Start: May 2003Est. completion: Dec 20091,035 patients
Phase 3Completed
NCT00245648Eli Lilly and Companyfibrinolytic therapy or combination reduced fibrinolytic therapy

Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI

Start: Jun 2001Est. completion: Oct 2007
Phase 3Completed
NCT00148460Boehringer IngelheimTNK-tPA

Trial to Compare the Efficacy and Safety of a Single Bolus of TNK-tPA (Tenecteplase, Metalyse®) With Accelerated Infusion of Rt-PA (Alteplase, Actilyse®) in Asian Patients With Acute Myocardial Infarction

Start: Mar 2001Est. completion: Feb 2006270 patients
Phase 3Completed
NCT02181998Boehringer IngelheimFull dose tenecteplase

A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital Setting

Start: Jul 20001,606 patients
Phase 3Completed
NCT02181985Boehringer IngelheimFull dose TNK-tPA

Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)

Start: May 20005,989 patients
Phase 3Completed
NCT02182011Boehringer IngelheimTenecteplase

A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI)

Start: May 200049 patients
Phase 3Completed
NCT01379261PhilipsCooling

Efficacy of Endovascular Catheter Cooling Combined With Cold Saline for the Treatment of Acute Myocardial Infarction

Start: Jun 2011Est. completion: Nov 2013120 patients
Phase 2/3Completed
NCT04421274UNION therapeuticsBone marrow mesenchymal stem cells transfer

Bone Marrow Mesenchymal Stem Cells Transfer in Patients With ST-segment Elevation Myocardial Infarction

Start: May 2008Est. completion: Jul 201143 patients
Phase 2/3Completed
NCT00077844SanofiPercutaneous coronary intervention

Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)

Start: Jan 2004Est. completion: Sep 20053,532 patients
Phase 2/3Completed
NCT07362446NyradaXolatryp

Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction

Start: Apr 2026Est. completion: Sep 2027300 patients
Phase 2Recruiting
NCT06139328Boehringer IngelheimBI 765845

IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack

Start: Dec 2023Est. completion: Dec 2025160 patients
Phase 2Terminated

Related Jobs

Medical Value Partner Cardiology & Critical Care

RocheRoche
Almere
1mo ago

Vice President Cardiovascular, Renal & Metabolism (Genentech Research and Early Development)

RocheRoche
South San Francisco
1mo ago
$446K - $551K/yr

Disease Area Leader (DAL), CVRM

RocheRoche
Basel
2mo ago

Search and Evaluation China Strategy Lead (CVRM)

RocheRoche
Shanghai
2mo ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

16 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 64,237 patients
30 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.